SureTrader Nadex Advertisement SureTrader
Home > Boards > US Listed > Biotechs >

Synthetic Biologics, Inc. (SYN)

Add SYN Price Alert      Hide Sticky   Hide Intro
Moderator: BooDog, TheHound
Search This Board: 
Last Post: 4/23/2017 12:52:45 AM - Followers: 196 - Board type: Free - Posts Today: 0

Synthetic Biologics

Synthetics Biologics, Inc., a biotechnology company, focuses on development of novel anti-infective biologics and drug candidates targeting specific pathogens that cause serious infections and other diseases. The company?s product candidates include Trimesta, which has completed phase II clinical trials for the treatment of relapsing-remitting multiple sclerosis and cognitive dysfunction in multiple sclerosis; SYN-010 that is in preclinical stage for the treatment of constipation-predominant irritable bowel syndrome; SYN-004, which is in preclinical stage for the treatment of clostridium difficile infection prevention; SYN-005 that is in preclinical stage for the treatment of pertussis; SYN-001, which is in discovery stage for the treatment of acinetobacter infection; and SYN-007 that is in discovery stage for the treatment of irritable bowel syndrome. It has a sublicense agreement with Meda AB for the development and commercialization of Effirma (flupirtine) for fibromyalgia in the United States, Canada, and Japan. The company was formerly known as Adeona Pharmaceuticals, Inc. and changed its name to Synthetics Biologics, Inc. in February 2012. Synthetics Biologics, Inc. was founded in 2001 and is based in Rockville, Maryland.

As of November 2, 2015 the registrant had 90,810,086 shares of common stock outstanding.

management team rule

board of directors rule

advisors rule


collaborators rule

The initiation of monocloncal antibody (mAb) development for the treatment of pertussis is the second of three infectious disease indications Synthetic Biologics intends to pursue as part of its August 2012 collaboration with Intrexon Corporation.

To further the development of this potential mAb therapy for pertussis, Synthetic Biologics has entered into an agreement with The University of Texas at Austin to license the rights to certain research and pending patents related to pertussis antibodies. These research efforts are being conducted at the Cockrell School of Engineering in the laboratory of Assistant Professor, Jennifer A. Maynard, Ph.D., the Laurence E. McMakin, Jr. Centennial Faculty Fellow in the McKetta Department of Chemical Engineering. Dr. Maynard brings to the project her expertise in defining the key neutralizing epitopes of pertussis toxin to optimize the potential efficacy of antibody therapeutics

SYN-001 rule

Acting as the body's army, antibodies are proteins, generally found in the bloodstream, that provide immunity in detecting and destroying pathogens, such as viruses and bacteria and their associated toxins. Monoclonal antibodies (mAbs) can also be designed and produced as therapeutic agents, utilizing protein engineering and recombinant production technologies. The mAbs being developed under the Synthetic Biologics’ collaboration with Intrexon are intended to supplement a patient's own immune system by providing the means to specifically and rapidly neutralize and/or clear specific pathogens and toxins of interest in a process known as “passive immunity”. Many pathogens that cause infectious diseases are innately resistant to, or over time have developed increased resistance to, antibiotics and other drugs. Synthetic Biologics intends to utilize Intrexon’s comprehensive suite of proprietary mAb design and recombinant protein production technologies to efficiently create potent candidate mAbs, SYN-001, for human testing and use to specifically treat Acinetobacter.

infectious diseases collaboration with Intrexon rule

Many infectious diseases are innately resistant to, or over time have developed increased resistance to, antibiotics and other drugs. In August 2012, Synthetic Biologics announced a second worldwide exclusive channel collaboration with Intrexon Corporation. Using Intrexon’s comprehensive suite of proprietary technologies and processes, Synthetic Biologics intends to develop and commercialize a series of monoclonal antibody (mAb) therapies for the treatment of certain infectious diseases not adequately addressed by existing therapies.

partnered program rule

Effirma™ for Fibromyalgia

Synthetic Biologics has partnered the development of Effirma (flupirtine), a centrally-acting investigational oral drug, for the treatment of fibromyalgia syndrome with Meda AB. Effirma is a selective neuronal potassium channel opener that also has NMDA receptor antagonist properties. Effirma is a non-opioid, non-NSAID, non-steroidal, analgesic. Preclinical data and clinical experience suggest that Effirma should also be effective for neuropathic pain since it acts in the central nervous system via a mechanism of action distinguishable from most marketed analgesics. Effirma is especially attractive because it operates through non-opiate pain pathways, exhibits no known abuse potential, and lacks withdrawal effects. In addition, no tolerance to its antinocioceptive effects has been observed. One common link between neuroprotection, nocioception and Effirma may be the N-methyl-D-aspartic acid glutamate system, a major receptor subtype for the excitotoxic neurotransmitter, glutamate. Effirma has strong inhibitory actions on N-methyl-D-aspartic acid-mediated neurotransmission. Flupirtine was originally developed by Asta Medica (subsequently acquired by Meda AB) and has been approved and is marketed by Meda AB in Europe since 1984, as well as other countries, for the treatment of pain. It has never been approved by the FDA for any indication.

On May 6, 2010, Synthetic Biologics and Pipex, its wholly owned subsidiary, entered into a sublicense agreement with Meda AB, a multi-billion dollar international pharmaceutical company, pursuant to which Meda AB assumed all future development costs and may commercialize flupirtine for fibromyalgia in the United States. As consideration for such sublicense, Synthetic Biologics received an up-front payment of $2.5 million and is entitled to milestone payments of $5 million upon the FDA’s acceptance of the New Drug Application (NDA) for flupirtine for fibromyalgia and $10 million upon FDA approval of such NDA. Pursuant to the sublicense agreement, Synthetic Biologics will also receive a 7% royalty on net sales of flupirtine for fibromyalgia in the United States, Canada and Japan, with such royalties being shared equally with Synthetic Biologic’s licensor, McLean Hospital, a Harvard teaching hospital.

Flupirtine is approved and marketed by Meda AB and its distributors in Europe and other countries for indications other than fibromyalgia and has been prescribed to millions of patients worldwide. Synthetic Biologics believes that such substantial human experience with flupirtine should greatly assist the FDA in its evaluation of the safety of flupirtine upon review of an NDA of flupirtine for fibromyalgia. According to Meda’s 2010 Annual Report, flupirtine for fibromyalgia is currently in Phase II development.

Fibromyalgia is a chronic and debilitating condition characterized by widespread pain and stiffness throughout the body, often accompanied by severe fatigue, insomnia and mood symptoms. According to the National Fibromyalgia Association, fibromyalgia affects an estimated 3-6% of the population worldwide, including an estimated 10 million patients in the U.S.

There are presently three FDA products approved for this indication in the United States – Lyrica®, Cymbalta® and Savella®. Flupirtine is differentiated from these products in that it employs a unique mode of action.

SEC filings

Finviz quote

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
SYN News: Synthetic Biologics Reports Preclinical Data Demonstrating SYN-005 Provides Protection from Pertussis in Neonatal Animal Stud... 04/19/2017 07:00:00 AM
SYN News: Statement of Changes in Beneficial Ownership (4) 03/16/2017 06:53:38 PM
SYN News: Synthetic Biologics to Present at the 29th Annual ROTH Conference 03/07/2017 07:00:00 AM
SYN News: Annual Report (10-k) 03/02/2017 05:06:20 PM
SYN News: Current Report Filing (8-k) 03/02/2017 04:15:52 PM
#6620  Sticky Note Link back for charts and links/dd. BooDog 11/30/15 06:33:49 AM
#7380   Great DD blackcat....Thanks Citrati 04/23/17 12:52:44 AM
#7379   A little extra PR for SYN today. Might blackcat 04/22/17 09:38:43 PM
#7378   We're good. I'm not, my deposit clears this BooDog 04/22/17 01:53:46 PM
#7377   Completely agree, think we see a move next Chunky Salsa 04/21/17 12:31:59 PM
#7376   I would call the share structure middle of Citrati 04/21/17 12:27:14 PM
#7375   MMs manipulate 24/7 but the problem is the Chunky Salsa 04/21/17 11:02:06 AM
#7374   Agreed. Want to keep the higher low for sure. Citrati 04/21/17 10:56:43 AM
#7373   That was a ton of selling this am Chunky Salsa 04/21/17 10:28:08 AM
#7372   I just want a higher high. To crash Citrati 04/21/17 09:57:33 AM
#7371   We need to make higher highs today and Chunky Salsa 04/21/17 08:41:01 AM
#7370   Todays large green volume bar is largest since Citrati 04/21/17 01:19:14 AM
#7369   History.... Citrati 04/21/17 01:09:25 AM
#7368   We've turned the RSI corner! It's billmick11 04/20/17 06:30:10 PM
#7367   Will this Dog ever bark again?? Theboy56 04/20/17 02:34:39 PM
#7366   .60 would be a solid 20% gain in Citrati 04/20/17 12:45:01 PM
#7365   Synthetic Biologics Unveils Positive Preclinical Data For Whooping Citrati 04/20/17 12:41:41 PM
#7364   Saw a block trade 400k shares at .50 Chunky Salsa 04/20/17 10:12:17 AM
#7363   Yeah, could go to .20 or it could Chunky Salsa 04/20/17 07:46:55 AM
#7362   If this wait until next month the bounce porgyrusty 04/18/17 06:42:04 PM
#7361   I'm in waiting for that big bounce eom Chunky Salsa 04/18/17 03:43:02 PM
#7360   Picked up some .47's. Tight stop if wrong. Citrati 04/18/17 12:34:17 PM
#7359   Looks like pinch time. But will it!? BooDog 04/11/17 02:19:30 PM
#7358   Agreed. Definitely a POS. porgyrusty 04/11/17 11:30:19 AM
#7357   Had to dump at .54....Can't hold such an scottsmith 04/11/17 10:20:32 AM
#7356   shheeeshhhh, closed low of day and under .50. Citrati 04/10/17 04:06:24 PM
#7355   Wow, what a POS this has turned out porgyrusty 04/10/17 04:01:02 PM
#7354   Good Question. Citrati 04/10/17 02:00:06 PM
#7353   Do we really need to go below the billmick11 04/10/17 01:43:36 PM
#7352   So far so good. Citrati 04/10/17 11:26:59 AM
#7351   May just be wishful thinking, you decide for Citrati 04/07/17 02:28:29 PM
#7350   RSI seems to be turning. Needs billmick11 04/06/17 07:16:37 PM
#7349   I'll just say, hindsight can be a real BooDog 04/06/17 01:49:14 PM
#7348   While I understand the sentiment, raising capital to Citrati 04/06/17 11:48:57 AM
#7347   Rooting for you to succeed. Citrati 04/06/17 11:39:34 AM
#7346   I have a feeling that the price per big orange 04/06/17 11:30:07 AM
#7345   Looks like a lower volume day is shaping scottsmith 04/06/17 09:59:08 AM
#7344   Purchased another 5000 shares at 0.53 today. Iam perfusionist 04/05/17 07:52:46 PM
#7343   Unreal what has happened here... hate it for Farmmarket1 04/05/17 05:36:01 PM
#7342   That is as low an ADX green reading Citrati 04/05/17 03:57:07 PM
#7341   RSI is at 16.6. It billmick11 04/05/17 11:56:45 AM
#7340   8 straight days of selling. Time for a bounce. porgyrusty 04/04/17 10:28:19 PM
#7339   lol, without a doubt. And SYN has BooDog 04/04/17 05:18:42 PM
#7338   holy smokes it's getting hot in here. syn TheHound 04/04/17 05:13:53 PM
#7337   Wow. $.45 cuts the market cap and a third porgyrusty 04/04/17 03:34:14 PM
#7336   100k market sell order will do it. noretreat 04/04/17 03:32:07 PM
#7335   God damn! .45!!! scottsmith 04/04/17 02:00:31 PM
#7334 at just under 54 cents. noretreat 04/04/17 01:48:57 PM
#7333   RSI is at 17. It will not noretreat 04/04/17 01:26:17 PM
#7332   Good luck. Pending adequate financing, this stock ericseb2003 04/04/17 01:24:04 PM
#7331   And I still have my .8's. BooDog 04/04/17 01:21:07 PM